Drugs / GT201
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT05724732 | Feb 2023 → May 2025 | neoplasm | RenJi Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT06834542 | Nov 2022 → Dec 2025 | female reproductive system neoplasm | Grit Biotechnology | Terminated | No outcome recorded Stop: Business |
| Phase 11 trial | ||||||
| Phase 1 | NCT05430360 | Jan 2022 → Dec 2025 | neoplasm | Grit Biotechnology | Terminated | No outcome recorded Stop: Business |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06144671 | Sep 2023 → Sep 2026 overdue | cancer | Grit Biotechnology | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05729399 | Sep 2022 → Dec 2025 | cancer | Grit Biotechnology | Terminated | No outcome recorded Stop: Business |
| Phase not applicable4 trials | ||||||
| — | NCT06519669 | Jul 2024 → Dec 2025 | lung cancer | Grit Biotechnology | Terminated | No outcome recorded Stop: Business |
| — | NCT06190275 | May 2024 → Apr 2027 expected | head and neck squamous cell carcinoma | Grit Biotechnology | Recruiting | No outcome recorded |
| — | NCT06235242 | Feb 2024 → Dec 2025 | non-small cell lung carcinoma | Grit Biotechnology | Terminated | No outcome recorded Stop: Business |
| — | NCT06191900 | Jun 2023 → Dec 2025 | female reproductive system neoplasm | Grit Biotechnology | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2025-11-07 | Grit Biotechnology | Results 沙砾生物受邀于2025 TIL Therapies Summit进行主题报告 gritbio.com ↗
在会议报告中，沙砾生物将展示 GT201 的设计原理、作用机制与临床前验证数据，以及来自12例实体瘤患者的安全性与初步疗效结果，其中包含2例完全缓解（CR）和多例部分缓解（PR）。 |
| 2025-05-29 | Grit Biotechnology | Results 沙砾生物在ASCO 2025公布多项TIL细胞疗法临床进展 gritbio.com ↗
在9例可评估患者中，GT201实现了55.6%的客观缓解率（ORR）和77.8%的疾病控制率（DCR），尤其是在头颈鳞癌和非小细胞肺癌等治疗难度较高的适应症中表现出卓越疗效。 |
| 2025-01-26 | Grit Biotechnology | Results 晚期头颈鳞癌患者绝境逢生：TIL 疗法点亮希望之光 gritbio.com ↗
TIL输注后3周后，右侧口底、颈部淋巴等多处病灶肿瘤缩小，出现临床部分缓解（PR），在第9周随访时影像显示所有病灶均消失，达到完全缓解（CR）。 |
| 2024-05-25 | Grit Biotechnology | Results 沙砾生物将在ASCO 2024展示细胞治疗领域最新研究成果 (2) GT201 gritbio.com ↗
沙砾生物此次展示了TIL注射液GT201的1期临床研究中的安全性和临床疗效数据。 |
| 2023-05-17 | Grit Biotechnology | Results 沙砾生物下一代基因编辑型TIL产品-GT201临床前及临床研究进展入选ASGCT和ASCO年会 gritbio.com ↗
GT201产品在首个人体实验中，在多个晚期实体瘤患者体内均表现出良好的安全性，并展示出稳定的扩增和初步临床疗效。 |
All press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-11-07 | Grit Biotechnology | 沙砾生物受邀于2025 TIL Therapies Summit进行主题报告 gritbio.com ↗ |
| 2025-05-29 | Grit Biotechnology | 沙砾生物在ASCO 2025公布多项TIL细胞疗法临床进展 gritbio.com ↗ |
| 2025-01-26 | Grit Biotechnology | 晚期头颈鳞癌患者绝境逢生：TIL 疗法点亮希望之光 gritbio.com ↗ |
| 2024-05-25 | Grit Biotechnology | 沙砾生物将在ASCO 2024展示细胞治疗领域最新研究成果 (2) GT201 gritbio.com ↗ |
| 2023-05-17 | Grit Biotechnology | 沙砾生物下一代基因编辑型TIL产品-GT201临床前及临床研究进展入选ASGCT和ASCO年会 gritbio.com ↗ |
| 2023-05-17 | Grit Biotechnology | Preclinical and clinical research updates of GRIT’s next-generation gene-edited TIL product GT201 wi gritbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GT201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05729399 ↗ |
| Modality | Cell therapy | “autologous tumor-infiltrating lymphocyte therapy” NCT05430360 ↗ |